DUBLIN - today announced the U.S. launch of the Solitaire(TM) X Revascularization Device - and its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading ...
MANSFIELD, Mass.-- (BUSINESS WIRE)-- Covidien (NYSE:COV), a leading global provider of healthcare products, today released the results of the Solitaire™ FR Thrombectomy for Acute Revascularization ...
The Solitaire (TM) FR revascularization device has been cleared by the U.S. Food and Drug Administration and is intended to restore blood flow to the brain in patients suffering acute ischemic stroke ...
Ischemic stroke, when blood clots block the blood vessels to the brain, represent about 87 percent of all strokes. Strokes affect 795,000 people in the U.S. each year. The highest death rates from ...
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the Solitaire TM FR Revascularization Device has been approved for investigational use in the Interventional ...
Use of a mechanical revascularization device in patients with acute ischemic stroke is associated with good clinical outcome and low risk of procedure- and device-related complications, according to a ...
Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™ FR Revascularization Dev
Add Yahoo as a preferred source to see more of our stories on Google. Covidien's Solitaire FR device is designed to restore blood flow in patients experiencing ischemic s ... Covidien's Solitaire FR ...
DUBLIN - April 30, 2019 - Medtronic plc (MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device - and its first use in patients for the treatment of acute ischemic stroke ...
Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™ FR Revascularization Dev
STAR Study Reviews Device Use in Blood Clot Removal Treatment for Patients Experiencing Acute Ischemic Stroke Covidien's Solitaire FR device is designed to restore blood flow in patients experiencing ...
System Offers New Options for Improving Outcomes in Treating Stroke; World`s Second-Leading Cause of Death, Third-Leading Cause of Disability DUBLIN - April 30, 2019 - Medtronic plc (MDT) today ...
Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™ FR Revascularization Dev
Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™FR Revascularization Device STAR Study Reviews Device Use in Blood Clot Removal Treatment for Patients Experiencing Acute ...
Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™ FR Revascularization Dev
MANSFIELD, Mass.--(BUSINESS WIRE)-- Covidien (NYS: COV) , a leading global provider of healthcare products, today released the results of the Solitaire™ FR Thrombectomy for Acute Revascularization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results